Sun Pharma Demands Generic Cancer Drug Market Exclusivity

Law360, Los Angeles (March 1, 2013, 10:38 PM EST) -- Sun Pharmaceutical Industries Ltd. urged a District of Columbia federal judge Friday to block the U.S. Food and Drug Administration from approving any generic versions of the oncology drug Zometa until the agency decides whether to grant 180-day market exclusivity to the Indian drugmaker.

Sun Pharma was the first pharmaceutical company to file an abbreviated new drug application to patent a Zometa generic and deserves “first-filer” status, the Friday complaint says. The exclusivity on Novartis Pharmaceuticals Corp.'s three patents covering its uses of zoledronic acid —...
To view the full article, register now.